157 related articles for article (PubMed ID: 38064927)
21. Are circulating metabolites important in pharmacokinetic drug-drug interactions? A retroanalysis of clinical data.
Zhao YS; Chen F; Li L
Curr Drug Metab; 2014; 15(8):767-90. PubMed ID: 25705906
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017.
Yu J; Petrie ID; Levy RH; Ragueneau-Majlessi I
Drug Metab Dispos; 2019 Feb; 47(2):135-144. PubMed ID: 30442649
[TBL] [Abstract][Full Text] [Related]
23. Prediction methods of drug-drug interactions of non-oral CYP3A4 substrates based on clinical interaction data after oral administrations - Validation with midazolam, alfentanil, and verapamil after intravenous administration and prediction for blonanserin transdermal patch.
Tomita Y; Yahata M; Hashimoto M; Nishimuta H; Kawaguchi H; Matsushita H; Kitamura A; Nishibe H; Natsui K; Watanabe T
Drug Metab Pharmacokinet; 2020 Aug; 35(4):345-353. PubMed ID: 32660818
[TBL] [Abstract][Full Text] [Related]
24. Recent progress in in vivo phenotyping technologies for better prediction of transporter-mediated drug-drug interactions.
Maeda K
Drug Metab Pharmacokinet; 2020 Feb; 35(1):76-88. PubMed ID: 31948854
[TBL] [Abstract][Full Text] [Related]
25. Calibrating the In Vitro-In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models.
Sane R; Cheung KWK; Kovács P; Farasyn T; Li R; Bui A; Musib L; Kis E; Plise E; Gáborik Z
Drug Metab Dispos; 2020 Dec; 48(12):1264-1270. PubMed ID: 33037044
[TBL] [Abstract][Full Text] [Related]
26. Using Endogenous Biomarkers to Derisk Assessment of Transporter-Mediated Drug-Drug Interactions: A Scientific Perspective.
Arya V; Reynolds KS; Yang X
J Clin Pharmacol; 2022 Dec; 62(12):1501-1506. PubMed ID: 35778968
[TBL] [Abstract][Full Text] [Related]
27. Robust physiologically based pharmacokinetic model of rifampicin for predicting drug-drug interactions via P-glycoprotein induction and inhibition in the intestine, liver, and kidney.
Asaumi R; Nunoya KI; Yamaura Y; Taskar KS; Sugiyama Y
CPT Pharmacometrics Syst Pharmacol; 2022 Jul; 11(7):919-933. PubMed ID: 35570332
[TBL] [Abstract][Full Text] [Related]
28. Can Mechanistic Static Models for Drug-Drug Interactions Support Regulatory Filing for Study Waivers and Label Recommendations?
Gomez-Mantilla JD; Huang F; Peters SA
Clin Pharmacokinet; 2023 Mar; 62(3):457-480. PubMed ID: 36752991
[TBL] [Abstract][Full Text] [Related]
29. Role of Hepatic Drug Transporters in Drug Development.
Liu H; Sahi J
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S11-22. PubMed ID: 27385168
[TBL] [Abstract][Full Text] [Related]
30. 2020 FDA Drug-drug Interaction Guidance: A Comparison Analysis and Action Plan by Pharmaceutical Industrial Scientists.
Sudsakorn S; Bahadduri P; Fretland J; Lu C
Curr Drug Metab; 2020; 21(6):403-426. PubMed ID: 32562522
[TBL] [Abstract][Full Text] [Related]
31. Simulations of Cytochrome P450 3A4-Mediated Drug-Drug Interactions by Simple Two-Compartment Model-Assisted Static Method.
Iga K; Kiriyama A
J Pharm Sci; 2017 May; 106(5):1426-1438. PubMed ID: 28089686
[TBL] [Abstract][Full Text] [Related]
32. Mechanistic Static Model based Prediction of Transporter Substrate Drug-Drug Interactions Utilizing Atorvastatin and Rifampicin.
Mitra P; Kasliwala R; Iboki L; Madari S; Williams Z; Takahashi R; Taub ME
Pharm Res; 2023 Dec; 40(12):3025-3042. PubMed ID: 37821766
[TBL] [Abstract][Full Text] [Related]
33. Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions.
Britz H; Hanke N; Taub ME; Wang T; Prasad B; Fernandez É; Stopfer P; Nock V; Lehr T
Pharm Res; 2020 Nov; 37(12):250. PubMed ID: 33237382
[TBL] [Abstract][Full Text] [Related]
34. Transporter biology in drug approval: regulatory aspects.
Maeda K; Sugiyama Y
Mol Aspects Med; 2013; 34(2-3):711-8. PubMed ID: 23506904
[TBL] [Abstract][Full Text] [Related]
35. Physiologically based pharmacokinetic modelling to predict drug-drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors.
Kollipara S; Ahmed T; Praveen S
Xenobiotica; 2023 May; 53(5):366-381. PubMed ID: 37609899
[TBL] [Abstract][Full Text] [Related]
36. Identification and quantitation of enzyme and transporter contributions to hepatic clearance for the assessment of potential drug-drug interactions.
Kimoto E; Obach RS; Varma MVS
Drug Metab Pharmacokinet; 2020 Feb; 35(1):18-29. PubMed ID: 31952912
[TBL] [Abstract][Full Text] [Related]
37. Drug-drug Interactions of Angiotensin Converting Enzyme Inhibitors Mediated by Metabolizing Enzymes and Transporters.
Sun P; Liu K
Curr Drug Metab; 2018; 19(13):1119-1129. PubMed ID: 30062958
[TBL] [Abstract][Full Text] [Related]
38. Hepatic transporter drug-drug interactions: an evaluation of approaches and methodologies.
Williamson B; Riley RJ
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1237-1250. PubMed ID: 29121476
[TBL] [Abstract][Full Text] [Related]
39. Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).
Duan P; Zhao P; Zhang L
Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):689-705. PubMed ID: 27858342
[TBL] [Abstract][Full Text] [Related]
40. Progress in the Quantitative Assessment of Transporter-Mediated Drug-Drug Interactions Using Endogenous Substrates in Clinical Studies.
Mochizuki T; Kusuhara H
Drug Metab Dispos; 2023 Sep; 51(9):1105-1113. PubMed ID: 37169512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
